华东医药股份有限公司 第一章 总则 第一条 为进一步完善华东医药股份有限公司（以下简称"公司"或"本公司"） 法人治理结构，明确总经理的职责，保障总经理高效、协调、规范地行使职权，根据 《中华人民共和国公司法》《上市公司治理准则》等法律法规和《华东医药股份有限公 司章程》（以下简称"公司章程"）的规定，并结合公司的实际情况，特制定本细则。 第二条 总经理是董事会领导下的公司行政负责人，应当遵守法律、行政法规和公 司章程的规定，履行诚信和勤勉的义务，负责贯彻落实董事会决议，主持公司的生产经 营和日常管理工作，并对董事会负责。 第二章 总经理的任职资格与任免程序 第三条 总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营管理能 力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统揽全局 的能力； （三）具有一定年限的企业管理或经济工作经历，精通本行，熟悉多种行业的生产 经营业务和掌握国家有关政策、法律、法规； （四）诚信勤勉、廉洁奉公、民主公道； （五）年富力强，有较强的使命感和积极开拓的进取精神。 第四条 有下列情形之一的，不得担任本公司总经理： ...

Core Points - The document outlines the procedures and requirements for East China Pharmaceutical Co., Ltd. to select and appoint accounting firms, ensuring compliance with relevant laws and regulations [1][2][12] - The selection process involves the audit committee, which is responsible for proposing, evaluating, and recommending accounting firms to the board of directors and shareholders [6][7][11] Group 1: General Provisions - The company must adhere to laws such as the Company Law and Securities Law when appointing accounting firms [1] - The selection of accounting firms must be approved by the audit committee, board of directors, and shareholders [1][2] Group 2: Quality Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet specific regulatory requirements [2] - Firms must have a good reputation and a record of quality management, with no significant penalties in the last three years related to securities and futures business [2][5] Group 3: Selection Procedures - The audit committee can initiate the selection process and is responsible for drafting policies and evaluating proposals [6][7] - Various selection methods include competitive negotiation, public bidding, and invitation bidding [3][4] Group 4: Evaluation Criteria - Evaluation factors for accounting firms include audit fees, qualifications, quality management, and risk management capabilities [5][6] - Quality management must account for at least 40% of the evaluation score, while audit fees should not exceed 15% [5] Group 5: Supervision and Reporting - The company must disclose information about the accounting firms, including service duration and audit fees, in annual reports [11] - The audit committee is tasked with monitoring compliance with laws and evaluating the performance of the appointed accounting firms [11][30]

Core Viewpoint - The report discusses the independent financial advisory opinion regarding the restricted stock incentive plan of East China Pharmaceutical Co., Ltd., focusing on the fairness and reasonableness of the plan for shareholders and its impact on the company's sustainable operation [2][3]. Group 1: Incentive Plan Overview - The restricted stock incentive plan was approved through necessary procedures, including independent directors' opinions on its benefits for the company's sustainable development [4][5]. - The plan involves granting restricted stocks to directors, senior management, middle management, and core technical personnel, with specific conditions for vesting and transfer restrictions [1][2]. Group 2: Stock Repurchase and Cancellation - The company plans to repurchase and cancel 5.60 thousand shares of restricted stock due to the departure of six individuals who no longer qualify for the incentive [13][14]. - The repurchase represents 1.21% of the total restricted stocks granted under the incentive plan and 0.003% of the company's total share capital before the repurchase [14]. - The adjusted repurchase price for the restricted stocks is set at 23.20 yuan per share, following the company's profit distribution plan [14]. Group 3: Approval and Compliance - The independent financial advisor confirms that the adjustments to the repurchase price and the cancellation of restricted stocks have obtained necessary approvals and comply with relevant laws and regulations [13][14]. - The company must still fulfill the shareholder meeting review process and disclose relevant information as per regulations [14].

Core Insights - Company East China Pharmaceutical has received FDA approval for its clinical trial application of HDM2012, a novel antibody-drug conjugate targeting MUC-17 for advanced solid tumors [1][2] - HDM2012 is a first-in-class biologic with global intellectual property rights, demonstrating good drug-like properties, safety, and efficacy in preclinical studies [1][2] - The ADC market is projected to grow significantly, with global sales expected to reach $64.7 billion by 2030, reflecting a compound annual growth rate of 30% [2] Company Developments - The clinical trial application for HDM2012 was submitted to the FDA in May 2025 and received approval shortly thereafter, with a similar application accepted in China in June 2025 [2] - East China Pharmaceutical has previously launched other ADC products, including the first-in-class drug Somatuzumab Injection, which received conditional approval in November 2024 [3] - The approval of HDM2012's clinical trial is a significant advancement in the company's R&D process, enhancing its competitiveness in the oncology treatment sector [3]

Core Insights - East China Pharmaceutical (华东医药) has made significant progress in the development of two innovative drugs, HDM2020 and HDM2012, which have received IND approvals in China and the US respectively [1][2][3] Drug Development Progress - HDM2012 is the world's first ADC targeting MUC-17, currently the only ADC in clinical research for this target, showing promising preclinical results for treating MUC-17 positive gastric, colorectal, and pancreatic cancers [2][3] - HDM2020 targets FGFR2b, a potential target associated with aggressive tumors like gastric and breast cancer, and has demonstrated strong anti-tumor activity in preclinical models [3] Clinical Trials and Approvals - HDM2012's clinical trial in China for advanced solid tumors was accepted by the National Medical Products Administration (NMPA) in June 2025 [3] - HDM2020 is the fourth ADC targeting FGFR2b to enter clinical trials, highlighting its clinical significance as recognized in the 2025 CSCO gastric cancer guidelines [3] Strategic R&D Initiatives - The company has built a differentiated product pipeline focusing on endocrine, autoimmune, and oncology therapies, with over 30 innovative oncology drug candidates, including ADCs [4] - Collaborations with companies like ImmunoGen and Heidelberg Pharma aim to strengthen the ADC innovation chain and ecosystem [4] Market Outlook - The global ADC market is projected to grow significantly, with sales expected to reach $64.7 billion by 2030, reflecting a compound annual growth rate of 30% [4] Recent Product Approvals - The ADC drug, Somatuzumab Injection (爱拉赫), received conditional approval in November 2024, with a supplementary application for regular approval submitted in March 2025 [5] - The ovarian cancer drug, Senaparib Capsules (派舒宁), was approved by NMPA in January 2025 [6] Company Vision - The dual approval of HDM2012 and HDM2020 signifies a major breakthrough in target innovation for Chinese pharmaceutical companies, showcasing the company's ambition in innovative R&D and its transition towards becoming a comprehensive innovation leader [7]

关于调整 2022 年限制性股票激励计划回购价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"公司"）于2025年06月27日召 开第十届董事会第三十四次会议审议通过了《关于调整2022年限制性 股票激励计划回购价格的议案》，根据公司2022年第一次临时股东大 会对董事会的相关授权，上述事项无须提交公司股东大会审议。现就 有关事项说明如下： 证券代码：000963 证券简称：华东医药 公告编号：2025-050 华东医药股份有限公司 一、2022年限制性股票激励计划已履行的决策程序和信息披露情 况 1、2022年8月8日，公司召开第十届董事会第二次会议及第十届 监事会第二次会议，审议通过了《关于公司<2022年限制性股票激励 计划（草案）及摘要>的议案》、《关于公司<2022年限制性股票激励计 划实施考核管理办法>的议案》、《关于公司<2022年限制性股票激励计 划管理办法>的议案》、《关于提请股东大会授权董事会办理股权激励 相关事宜的议案》。独立董事就本激励计划是否有利于公司的持续发 展及是否存在损害公司及全体股东利 ...

关于 华东医药股份有限公司 2022 年限制性股票激励计划 调整限制性股票回购价格及回购注销部分限制性股票 之 法律意见书 浙江天册律师事务所 法律意见书 二〇二五年六月 1 法律意见书 浙江天册律师事务所 关于华东医药股份有限公司 2022 年限制性股票激励计划 调整限制性股票回购价格及回购注销部分限制性股票之 法律意见书 编号：TCYJS2025H1016 致：华东医药股份有限公司 浙江天册律师事务所（以下简称"本所"）接受华东医药股份有限公司（以 下简称"公司"）委托，担任公司 2022 年限制性股票激励计划（以下简称"本次 股权激励计划"或"本激励计划"）的专项法律顾问，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）等有关法律 法规的规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，现就本 次股权激励计划调整限制性股票回购价格（以下简称"本次调整回购价格"）及 回购注销部分限制性股票（以下简称"本次回购注销"）相关事项出具本法律意 见书。 为出具本法律意见书，本所依据《律师 ...

证券简称：华东医药 证券代码：000963 国盛证券有限责任公司 关于 华东医药股份有限公司 2022 年限制性股票激励计划调整回购价格 及回购注销部分限制性股票事项 独立财务顾问报告 独立财务顾问 （江西省南昌市新建区子实路 1589 号） 二〇二五年六月 之 | | | 目录 1 | | --- | --- | --- | | 第一章 | 释义 | 2 | | 第二章 | 声明 | 3 | | 第三章 | 基本假设 | 4 | | 第四章 | 本激励计划的授权与批准 | 5 | | 第五章 | 独立财务顾问意见 | 10 | | 华东医药、公司、上市公司 | 指 | 华东医药股份有限公司 | | --- | --- | --- | | 国盛证券、本独立财务顾问、 | 指 | 国盛证券有限责任公司 | | 独立财务顾问 | | | | 股权激励计划、激励计划、 | 指 | 华东医药股份有限公司 2022 年限制性股票激励计划 | | 本计划 | | | | 限制性股票 | 指 | 公司根据本计划规定的条件和价格，授予激励对象一定数 | | | | 量的公司股票，该等股票设置一定期限的限售期，在达到 | | ...

华东医药股份有限公司 董事会审计委员会议事规则 第一章 总则 第一条 为健全和规范华东医药股份有限公司（以下简称"公司"）董事会审计委 员会的议事和决策程序，提高审计委员会的工作效率和科学决策的水平，保证审计委员 会工作的顺利进行，依据《中华人民共和国公司法》（以下简称《公司法》）、《上市 公司治理准则》《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规及 《华东医药股份有限公司章程》（以下简称"公司章程"）、《华东医药股份有限公司 董事会议事规则》等规定，制定本议事规则。 第二章 人员组成 第二条 审计委员会成员为三名，为不在公司担任高级管理人员的董事，其中独立 董事二名，由独立董事中会计专业人士担任召集人，审计委员会成员及召集人由董事会 选举产生。 第三条 审计委员会成员应当勤勉尽责，切实有效地监督、评估公司内外部审计工 作，促进公司建立有效的内部控制并提供真实、准确、完整的财务报告。 审计委员会成员应当具备履行审计委员会工作职责的专业知识和经验。 第四条 审计委员会设召集人一名，由独立董事中的会计专业人士担任，负 ...

董事会可持续发展（ESG）委员会议事规则 第一章 总则 第一条 为健全和规范华东医药股份有限公司（以下简称"公司"）董事会可持续发 展（ESG）委员会的议事和决策程序，提高可持续发展（ESG）委员会的工作效率和科 学决策的水平，保证可持续发展（ESG）委员会工作的顺利进行，依据《中华人民共和 国公司法》（以下简称《公司法》）、《上市公司治理准则》《上市公司独立董事管理 办法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规及《华东医药股份有限公司章程》（以下简 称"公司章程"）、《华东医药股份有限公司董事会议事规则》等规定，制定《董事会 可持续发展（ESG）委员会议事规则》（以下简称"本议事规则"）。 第二章 人员组成 第二条 可持续发展（ESG）委员会成员由三至五名董事组成，其中至少包括一名独 立董事。可持续发展（ESG）委员会成员由董事会选举产生。 第三条 可持续发展（ESG）委员会成员应熟悉国家有关法律、法规和公司的经营管 理；有较强的综合分析和判断能力，能判断涉及公司发展战略、重大投资以及 ESG方面 的问题，具备独立工作的能力，并不断加 ...